Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-9821 in Healthy Participants and COPD Patients
NCT07567872Phase 1Recruiting
- Sponsor
- Hengrui Therapeutics
- Start
- Jul 2026
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial in chronic obstructive pulmonary disease (COPD) comparing HRS-9821 Powder for Inhalation with Placebo (2 arms). Primary endpoint: Change from baseline in the rate of adverse events at 26 days. Started Jul 2026; status: recruiting.
02
Drugs
HRS-9821
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT07567872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07567872.